TScanTherapeutics对扩大股票发行定价以筹集1.5亿美元

2024-04-17 15:37

TScan Therapeutics (NASDAQ:TCRX) announces the pricing of its upsized underwritten public offering of 2,472,581 shares of its voting common stock at $7.13 per share, with an expected gross proceeds of $150.1 million.
The offering was increased from the previously announced $125 million to $150 million.
In addition, TScan Therapeutics (TCRX) is offering pre-funded warrants to investors to purchase up to 18,577,419 shares of its voting common stock for $7.1299 per pre-funded warrant, less the exercise price.
In connection with the offering, the company has granted the underwriters a 30-day option to purchase up to an additional 3,157,500 shares of its voting common stock at the public offering price.
The offering is expected to close on April 19, 2024.
The company intends to use the net proceeds from the offering for general corporate purposes.
Upon the closure of the offering, the company expects that its existing cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.

More on TScan Therapeutics